Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

BACKGROUND: Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6537200/
https://ncbi.nlm.nih.gov/pubmed/31138244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5600-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares